

## Letters to Editor

### Myeloma and diabetes mellitus

DOI: 10.4103/2278-330X.130469

Dear Editor,

The recent article on “myeloma and diabetes mellitus” is interesting.<sup>[1]</sup> Ali *et al.*, noted that “the treatment of multiple myeloma and diabetes mellitus is multifaceted.”<sup>[1]</sup> In fact, diabetes mellitus is a common disorder in the present day. It is no doubt that diabetes mellitus can be seen in cancerous patients. For the concomitant diabetes mellitus and myeloma, a recent report by Ahmed *et al.*, also proposed for the importance of this problem.<sup>[2]</sup> The concern is on the interrelationship between cancer and myeloma. It is proposed that the use of high doses of glucocorticoids in management of myeloma can result in diabetes mellitus. The follow up of blood glucose for the early detection of diabetes mellitus in the patients with myeloma is suggested.<sup>[3]</sup> On the other hand, Snowden *et al.*, reported that “the plasma cell tumor was associated with excessive production of insulin-like peptides with

consequent reduction in the blood glucose level.”<sup>[4]</sup> Hence, the observation of significant unexplained reduction of blood glucose in diabetic patient with myeloma might require intensive investigation on progress of malignancy.

**Sora Yasri, Viroj Wiwanitkit<sup>1,2</sup>**

Primary Care Unit, KMT Center, Bangkok, Thailand, <sup>1</sup>Visiting Professor, Hainan Medical University, China, <sup>2</sup>Visiting Professor, Faculty of Medicine, University of Nis, Serbia

**Correspondence to:** Dr. Sora Yasri,

E-mail: sorayasri@outlook.co.th

### References

1. Ali MA, Ahmed YA, Ibrahim A. Clinical challenges: Myeloma and concomitant type 2 diabetes. *South Asian J Cancer* 2013;2:290-5.
2. Ahmed YA, Eltayeb A. Clinical challenges: Myeloma and concomitant type 2 diabetes. *Int J Hematol Oncol Stem Cell Res* 2013;7:34-41.
3. Pospíšilová Y, Adam Z. Disorder of glucose metabolism regulation in patients with multiple myeloma treated with high doses of corticosteroids at our clinic in 2004. *Vnitr Lek* 2007;53:18-23.
4. Snowden JA, Greaves M, Page K. Reversal of diabetes associated with escape of myeloma: Evidence for inappropriate IGF-II secretion. *Br J Haematol* 1994;87:202-4.